Health
PHARMAC opens consultation to address New Zealand’s biggest health issue1 – PRWire
Boehringer Ingelheim New Zealand welcomes a major PHARMAC proposal2 which could see up to 50,000 New Zealanders with type 2 diabetes and high risk of heart and kidney complications receive funded access to a medicine that not only lowers blood sugar, but
Boehringer Ingelheim New Zealand welcomes a major PHARMAC proposal2 which could see up to 50,000 New Zealanders with type 2 diabetes and high risk of heart and kidney complications receive funded access to a medicine that not only lowers blood sugar, but also reduces the risk of dying from heart complications.3,4
Under the new proposal, from 1December 2020, Jardiance (empagliflozin) would become the first and only oral diabetes medicine on New Zealands Pharmaceutical Schedule2 proven to deliver…
-
Business20 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Noosa News16 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
Noosa News8 hours agoDistress call sparks rescue operation for capsized sailor near North Stradbroke Island
-
Business8 hours agoBell Potter names more of the best ASX 200 stocks to buy in April